GNH USA

Europe — EMA

Ivabradina Viatris (Ivabradine Oxalate)

GNH USA supplies Ivabradina Viatris (Ivabradine), a If channel inhibitor for chronic stable angina and heart failure with reduced ejection fraction.

Ivabradine Oxalate

Request sourcing

1
Pack/s

What is Ivabradine Oxalate?

Ivabradine, the active ingredient in Ivabradina Viatris, is an If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is used in chronic stable angina and heart failure with reduced ejection fraction in adults.

GNH USA supplies Ivabradina Viatris as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Ivabradine Oxalate used for?

Ivabradina Viatris is used in cardiovascular conditions that involve elevated heart rate.

- Chronic stable angina pectoris: improves exercise tolerance by lowering heart rate without affecting myocardial contractility. - Heart failure with reduced ejection fraction (HFrEF): decreases hospitalization risk by reducing heart rate in patients already receiving guideline‑directed therapy.

What are the side effects of Ivabradine Oxalate?

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Bradycardia: resting heart rate falls below the intended range. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or general weakness. - Blurred vision.

Serious or Rare Side Effects: - Severe bradycardia leading to syncope. - Atrial fibrillation or other arrhythmias. - Symptomatic hypotension. - High‑grade atrioventricular block. - Persistent visual impairment. - Allergic reactions such as rash, angioedema, or anaphylaxis.

What precautions apply to Ivabradine Oxalate?

Before initiating therapy, clinicians should evaluate patient‑specific factors.

- Dose adjustment: reduce dose in patients with moderate hepatic impairment. - Monitor heart rate: avoid use if resting heart rate is <60 bpm. - Avoid concomitant strong CYP3A4 inhibitors: may increase ivabradine exposure. - Caution in sick‑sinus syndrome or atrioventricular block: may exacerbate bradyarrhythmias. - Pregnancy and lactation: safety not established; use only if clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and light.

What does Ivabradine Oxalate interact with?

Ivabradina Viatris may interact with several medicines that affect heart rate or metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole): increase plasma levels. - Co‑administration with other bradycardic agents (beta‑blockers, digoxin): risk of excessive heart‑rate reduction. - Diltiazem or verapamil: potentiate bradycardia via CYP3A4 inhibition.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Certain antidepressants that affect autonomic tone (e.g., SSRIs): monitor heart rate. - Loop or thiazide diuretics: watch for electrolyte shifts that could influence cardiac conduction.

Frequently asked questions

What conditions is Ivabradina Viatris used for?+
Ivabradina Viatris is indicated for chronic stable angina pectoris and for heart failure with reduced ejection fraction (HFrEF) in adults. In both settings the drug lowers heart rate, helping to relieve angina symptoms and to improve outcomes in patients already receiving standard heart‑failure therapy.
How does ivabradine work to lower heart rate?+
Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, which is responsible for spontaneous pacemaker activity. By inhibiting this current, the drug slows the rate of depolarisation during phase 4, resulting in a reduced resting heart rate while preserving contractile function and blood pressure.
What is the usual dose of Ivabradina Viatris?+
The dose of Ivabradina Viatris is individualized by the prescribing clinician based on the patient’s heart‑rate target, renal and hepatic function, and concomitant therapies. The prescriber determines the appropriate strength, titration schedule, and maintenance dose for each patient.
Is Ivabradina Viatris safe during pregnancy or breastfeeding?+
Safety data for ivabradine in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.
How do I order Ivabradina Viatris from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.
How does Ivabradina Viatris compare with beta‑blockers?+
Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on beta‑adrenergic receptors and have broader cardiovascular effects, which may be advantageous or limiting depending on the patient’s comorbidities.
What are the recommended storage conditions for Ivabradina Viatris?+
Ivabradina Viatris should be stored at ambient temperature, below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture and direct light, and ensure they are out of reach of children.
How is Ivabradina Viatris administered?+
The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not chewed or crushed, to maintain consistent absorption.
What are the most serious risks associated with Ivabradina Viatris?+
Serious risks include severe bradycardia, atrial fibrillation, high‑grade atrioventricular block, symptomatic hypotension, and rare visual disturbances that may be persistent. Patients should be monitored for these events, especially during dose titration or when combined with other heart‑rate‑lowering agents.
Who should not use Ivabradina Viatris?+
Ivabradina Viatris is contraindicated in patients with a resting heart rate below 60 bpm, those with acute decompensated heart failure, sick‑sinus syndrome, second‑ or third‑degree atrioventricular block (unless a pacemaker is present), and in individuals taking strong CYP3A4 inhibitors without appropriate dose adjustment.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Ivabradine Oxalate
Route
Oral Use
Manufacturer
Viatris Limited
Origin
EU

Related products

Brediwal

Brediwal

Ivabradine Oxalate

Sandoz Pharmaceuticals D.D.
EU
Ivabradin Heumann

Ivabradin Heumann

Ivabradine Oxalate

Heumann Pharma Gmbh & Co. Generica Kg
EU
Ivabradin Sandoz

Ivabradin Sandoz

Ivabradine Oxalate

Sandoz Gmbh
EU
Ivabradina Mylan Pharma

Ivabradina Mylan Pharma

Ivabradine Oxalate

Mylan S.P.A.
EU